An enlarged prostate is one of the most common conditions in medicine - and one of the most misunderstood. Roughly 50% of men have histological evidence of benign prostatic hyperplasia (BPH) by age 50, and 80% by age 80. Yet most men either suffer silently for years, or assume that their urinary symptoms are simply "what happens when you get older" and therefore not treatable. Both assumptions are wrong.
BPH is not cancer. It does not become cancer. But left untreated, it can damage the bladder, stretch the ureters, and injure the kidneys. And crucially - the urinary symptoms it causes at 55 or 65 are very different from those at 45. This guide explains what BPH is, how to recognise it at each stage of life, and - most importantly - what can be done about it.
What Is BPH? Not Cancer - A Natural Ageing Process
The prostate is a walnut-sized gland sitting at the base of the bladder, surrounding the urethra (the tube through which urine passes). Its function is to produce seminal fluid. From around age 30–35, the transition zone of the prostate (the inner portion immediately surrounding the urethra) begins to grow under the influence of dihydrotestosterone (DHT) - a potent androgen derived from testosterone by the enzyme 5-alpha reductase.
As the transition zone enlarges over decades, it progressively narrows the urethral lumen - reducing urine flow and forcing the bladder to work harder to empty. Over time, the bladder wall thickens (detrusor hypertrophy), the bladder becomes less compliant, and the symptoms that define BPH emerge. This is a universal biological process - every man's prostate grows with age. Whether it causes symptoms depends on the anatomical relationship between the prostate, urethra, and bladder - which is why some men with very large prostates are barely troubled, while others with smaller glands have significant obstruction.
The IPSS - Measuring How Serious Your Symptoms Are
The International Prostate Symptom Score (IPSS) is a validated, 7-question questionnaire that quantifies urinary symptoms and guides treatment decisions. Each question is scored 0–5, giving a maximum of 35. An additional "quality of life" question asks how you would feel if you had to live with your current urinary symptoms for the rest of your life.
IPSS Score Interpretation:
Score 0–7 (Mild) - Watchful waiting and lifestyle modification. Reassess annually.
Score 8–19 (Moderate) - Medical treatment indicated. Alpha-blockers with or without 5-ARIs depending on gland size.
Score 20–35 (Severe) - Medical treatment ± surgical referral. Surgery if medications fail or complications are present.
The IPSS is not a diagnostic test - it is a symptom severity tool. A high IPSS does not mean BPH; a low IPSS does not exclude it. The score guides how aggressively treatment should be pursued and provides a baseline to measure treatment response over time.
Voiding vs Storage Symptoms - What BPH Actually Feels Like
BPH produces two distinct categories of lower urinary tract symptoms (LUTS):
| Voiding Symptoms (Obstructive) | Storage Symptoms (Irritative) |
|---|---|
| Weak or slow urinary stream | Urgency - sudden, compelling urge to urinate |
| Straining to start urination | Frequency - urinating more than 8 times per day |
| Intermittent stream (start/stop) | Nocturia - waking 2 or more times at night to urinate |
| Terminal dribbling | Urgency incontinence - leaking before reaching the toilet |
| Sensation of incomplete bladder emptying | Dysuria - burning or discomfort on urination |
Voiding symptoms are caused directly by mechanical obstruction at the prostate. Storage symptoms arise secondary to bladder overactivity - the bladder muscle becomes irritable and spasmodic after years of working against obstruction. Both respond to treatment, but storage symptoms may persist even after obstruction is relieved if bladder changes are long-standing.
What Happens If BPH Is Left Untreated?
Many men tolerate mild BPH symptoms for years without seeking help. This is acceptable for mild IPSS scores - but moderate to severe untreated BPH can lead to serious, sometimes irreversible complications:
- Acute urinary retention (AUR) - a sudden, painful inability to urinate at all, requiring emergency catheterisation. AUR occurs in approximately 2% of men with moderate BPH per year, rising sharply with age and prostate size. It is frequently triggered by cold weather, dehydration, alcohol, or medications (particularly antihistamines and decongestants).
- Bladder wall damage (detrusor failure) - years of straining against obstruction thickens and eventually weakens the bladder muscle. An atonic, poorly contracting bladder ("underactive bladder" or detrusor failure) may not recover even after the obstruction is surgically relieved.
- Bladder stones - urinary stasis from incomplete emptying promotes crystal formation. Bladder stones cause haematuria, painful urination, and recurrent infections, and must be removed surgically.
- Recurrent urinary tract infections - residual urine after voiding is a growth medium for bacteria. Men with significant post-void residuals are at high risk of repeated UTIs and epididymo-orchitis.
- Hydronephrosis and kidney damage - in severe, long-standing obstruction, back-pressure of urine can stretch the ureters and damage the kidneys. This is called obstructive uropathy and, if prolonged, causes permanent loss of kidney function (chronic kidney disease).
The BPH Treatment Ladder: From Lifestyle to Surgery
Step 1: Lifestyle Modification (All Severities)
Reducing fluid intake after 6 PM (to control nocturia), limiting caffeine and alcohol, treating constipation, and reviewing medications that worsen urinary symptoms (antihistamines, antidepressants) can meaningfully improve IPSS scores without any drug treatment. Regular moderate exercise also reduces BPH symptom severity in population studies.
Step 2: Alpha-Blockers (Moderate Symptoms)
Alpha-1 adrenergic receptor blockers - tamsulosin 0.4 mg, alfuzosin 10 mg, silodosin 8 mg - relax smooth muscle in the prostate, bladder neck, and urethra. They improve urinary flow rates by 20–30% and significantly reduce IPSS within 2–4 weeks. They do not reduce prostate size. Side effects include retrograde ejaculation (particularly silodosin and tamsulosin) and postural hypotension (less common with uroselective agents).
Step 3: 5-Alpha Reductase Inhibitors (Large Prostates >40 mL)
Finasteride 5 mg and dutasteride 0.5 mg block the conversion of testosterone to DHT, reducing prostate volume by 20–30% over 6–12 months. They reduce the risk of acute urinary retention and the need for surgery by approximately 50% in large glands. The MTOPS and CombAT trials established that combination therapy (alpha-blocker + 5-ARI) is superior to either alone for large prostates or moderate-severe symptoms.
Step 4: Surgery - When Medication Is Not Enough
Surgery is indicated when: medications fail to adequately control symptoms; complications occur (urinary retention, bladder stones, recurrent infections, renal impairment); or the patient prefers a definitive solution over long-term medication. The two main surgical options at Apollo Hospital Gurugram are:
- HoLEP (Holmium Laser Enucleation of the Prostate) - the current international gold standard. Works on any prostate size (including giant prostates over 200 mL). The catheter is removed within 24 hours. No blood transfusion risk. Durable results lasting 15+ years. Suitable for patients on blood thinners.
- TURP (Transurethral Resection of the Prostate) - the traditional endoscopic standard, highly effective for moderate-sized prostates (30–80 mL). Bipolar TURP (plasma kinetic) has largely replaced monopolar TURP, with improved safety profile. Still an excellent choice in many clinical scenarios.
PSA Monitoring and the Cancer Question
BPH elevates PSA (Prostate-Specific Antigen) - the larger the prostate, the higher the PSA from benign tissue alone. A PSA of 3–6 ng/mL in a man with a 60–80 mL prostate may be entirely explained by BPH. However, PSA monitoring during BPH treatment is essential because both conditions (BPH and prostate cancer) coexist in a significant proportion of men over 60.
Important: 5-alpha reductase inhibitors (finasteride, dutasteride) reduce PSA by approximately 50% after 6 months of treatment. If a man's PSA does not fall by at least 50% after 12 months on a 5-ARI, or if PSA rises during treatment, prostate cancer must be excluded with MRI and possible biopsy. This "PSA doubling rule" is a critical safety principle. Read more about PSA testing and what your result means.
Red flags that suggest prostate cancer rather than (or in addition to) BPH: rapidly rising PSA; PSA velocity >0.75 ng/mL per year; hard or nodular prostate on digital rectal examination; haematuria; bone pain; constitutional symptoms (weight loss, night sweats). Any of these warrants urgent MRI prostate and urology assessment - read our dedicated BPH treatment page for a full comparison of management options.
Video: Enlarged Prostate - Symptoms, Treatment and Surgery Options
Bothered by urinary symptoms?
Dr. Nitin Shrivastava offers a complete BPH assessment - IPSS scoring, ultrasound, uroflowmetry, PSA - and a clear, personalised treatment plan at Apollo Hospital Gurugram.
Book ConsultationFrequently Asked Questions
No - benign prostatic hyperplasia (BPH) and prostate cancer are entirely separate conditions. BPH is a non-cancerous overgrowth of the transition zone of the prostate, driven by age-related hormonal changes. It does not transform into prostate cancer, does not increase your risk of prostate cancer, and is not caused by cancer. A man can have BPH, prostate cancer, or both simultaneously - but having one does not cause the other. The key distinction is made by PSA testing, digital rectal examination, and if needed, MRI and biopsy.
No food has been proven to shrink an already-enlarged prostate. However, certain dietary choices are associated with lower rates of BPH progression in population studies: lycopene-rich foods (cooked tomatoes, watermelon), zinc (pumpkin seeds, nuts), and a diet low in saturated fat and red meat. Reducing caffeine, alcohol, and spicy food reduces irritative urinary symptoms in many men, though they do not change prostate size. Saw palmetto is widely used but evidence from high-quality trials is inconsistent - it is not recommended as a substitute for medical treatment in symptomatic BPH.
Mild to moderate BPH can be very effectively managed with medications - alpha-blockers (tamsulosin, alfuzosin) relax the smooth muscle of the prostate and urethra within days; 5-alpha reductase inhibitors (finasteride, dutasteride) reduce prostate volume by 20–30% over 6 months and are most effective in larger glands. Combination therapy works better than either alone for large prostates. However, medications do not cure BPH - they control symptoms. If medications fail, produce side effects, or if complications occur (urinary retention, bladder damage, recurrent infection), surgery (HoLEP or TURP) is required. Surgery is the only treatment that definitively and lastingly resolves BPH obstruction.
An enlarged prostate is diagnosed by a combination of symptom assessment (using the International Prostate Symptom Score, IPSS), digital rectal examination (DRE), PSA blood test, and ultrasound. Urinary symptoms alone are not sufficient - symptoms of BPH overlap with overactive bladder, urinary tract infection, and urethral stricture. A transrectal or transabdominal ultrasound measures prostate volume accurately (BPH is usually defined as volume over 30 mL). A uroflowmetry test (measuring urinary flow rate) and post-void residual measurement complete the functional assessment. A urologist combines all this data to grade severity and guide treatment.
The best treatment depends on prostate size, symptom severity, complication status, and patient preference. For mild symptoms (IPSS under 8): watchful waiting with lifestyle changes. For moderate symptoms (IPSS 8–19): alpha-blockers alone or in combination with 5-alpha reductase inhibitors for large glands. For severe symptoms, failed medication, or complications: surgery. HoLEP (Holmium Laser Enucleation of the Prostate) is now the international gold standard for surgical BPH treatment - it works on any prostate size, has no blood transfusion risk, produces durable results, and the catheter comes out within 24 hours. TURP remains a good option for moderate-sized prostates. Both procedures are available at Apollo Hospital Gurugram.